Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 267-274

  Berger, Karin ^a   Hessel, F ^b,c   Kreuzer, J ^d   Smala, A ^e   Diener, H C ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Gait Lab Social Pediatric Centre Children's Clinic St Vincenz Hospital   (Germany)

^e Medical Economics Research Group MERG   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cardiovascular diseases; Cost effectiveness; Myocardial infarction; Peripheral vascular disease; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ARTERY DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; GERMANY; HEART INFARCTION; HUMAN; SURVIVAL;

EID: 38549092569     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X253762     Document Type: Article

References (23)

1. Ringleb PA, Schellinger PD, Schwark C. Clopidogrel in the management of cerebrovascular events. Int J Clin Pract 2004;4:402-10
2. World Health Organization (WHO). Der Europäische Gesundheitsbericht 2002. WHO Regional Office, Copenhagen; 2004. European Series No 97
3. Statistisches Bundesamt. Gesundheitberichterstattung des Bundes [Federal Health Report]. www.gbe-bund.de [Nov 22, 2004]
4. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
5. Jones L, Griffin S, Palmer S, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004;8:ii-iv,1-196
6. Schellinger PD, Juttler E, Meyding-Lamade UK, Schwark C. The value of platelet inhibitors in secondary prophylaxis of stroke - a review. Fortschr Neurol Psychiatr 2004;5:270-1
7. Diener HC, Rupprecht HJ, Willich SN, et al. Cost of atherothrombotic diseases - myocardial infarction (MI), ischaemic stroke (IS) and peripheral arterial occlusive disease (PAD). J Public Health 2005;13:216-24
8. Annemans L, Lamotte M, Levy E, Lenne X. Cost-effectiveness of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. JME 2003;6:55-68
9. Levy E, Gabriel S, Carita P, Dinet J. An economic evaluation of clopidogrel in secondary prevention of ischemic events: high risk populations. Value Health 2002;6:477-8
10. Rudelli G, Annemans L, Spiesser J, et al. An economic evaluation of clopidogrel vs. Aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients in Italy [poster]. 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Hamburg, Germany, Oct 24-26, 2004
11. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267-70
12. Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health 2004;5:627-35
13. Brüggenjürgen B, Rupprecht H-J, Willich SN, et al. Cost of atherothrombotic diseases - myocardial infarction (MI), ischaemic stroke (IS) and peripheral arterial occlusive disease (PAD). J Public Health 2005;13:216-224
14. Rote Liste Service GmbH (ed.) Rote Liste Win 2004/I, Version 3.3., ECV Edition Cantor Verlag, 2004
15. Delphi-Panel data, costs updated in 2004, data available on request. The whole Delphi process is described in citation 4.
16. Hense HW, Schulte H, Löwel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;24:937-45
17. Schwabe U, Paffrath D (eds.). Arzneiverordnungsreport 2003, Berlin: Springer Verlag, 2004, ISBN 3-540-40188-1
18. Hannoveraner Konsensgruppe. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation. Med Klin 2000;95:52-5
19. American Heart Association. International Cardiovascular Statistics. 2004. www.americanheart.org
20. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med 2004;12:797-806
21. Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. Am J Med 1999;6:568-72
22. Probstfield JL. How cost-effective are new preventive strategies for cardiovascular disease? Am J Cardiol 2003;10A:22-7G
23. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;5:417-30